Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

332 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
TRF2 as novel marker of tumor response to taxane-based therapy: from mechanistic insight to clinical implication.
Iachettini S, Terrenato I, Porru M, Di Vito S, Rizzo A, D'Angelo C, Petti E, Dinami R, Maresca C, Di Benedetto A, Palange A, Mulè A, Santoro A, Palazzo A, Fuso P, Stoppacciaro A, Vici P, Filomeno L, Di Lisa FS, Arcuri T, Krasniqi E, Fabi A, Biroccio A, Zizza P. Iachettini S, et al. Among authors: fabi a. J Exp Clin Cancer Res. 2024 Mar 9;43(1):75. doi: 10.1186/s13046-024-02998-w. J Exp Clin Cancer Res. 2024. PMID: 38459559 Free PMC article.
Multigenic panels in breast cancer: Clinical utility and management of patients with pathogenic variants other than BRCA1/2.
Fabi A, Cortesi L, Duranti S, Cordisco EL, Di Leone A, Terribile D, Paris I, de Belvis AG, Orlandi A, Marazzi F, Muratore M, Garganese G, Fuso P, Paoletti F, Dell'Aquila R, Minucci A, Scambia G, Franceschini G, Masetti R, Genuardi M. Fabi A, et al. Crit Rev Oncol Hematol. 2024 Sep;201:104431. doi: 10.1016/j.critrevonc.2024.104431. Epub 2024 Jul 6. Crit Rev Oncol Hematol. 2024. PMID: 38977141 Review.
The role of body composition in neurological and hematologic toxicity in a retrospective analysis of 120 breast cancer patients undergoing neoadjuvant chemotherapy: the COMBOTOX study.
Di Leone A, Filippone A, Maggiore C, Rossi MM, Rossi C, Di Micco A, Forcina L, Franco A, Ionta L, Fabi A, Paris I, Scardina L, Sanchez AM, Pafundi PC, Franceschini G, Masetti R, Magno S. Di Leone A, et al. Among authors: fabi a. Breast Cancer Res Treat. 2024 Dec 4. doi: 10.1007/s10549-024-07553-x. Online ahead of print. Breast Cancer Res Treat. 2024. PMID: 39630164
Male breast cancer: a multicenter study to provide a guide for proper management.
Lissidini G, Nicosia L, Sargenti M, Cucchi MC, Fabi A, Falco G, Gardani M, Grilz G, Maugeri I, Murgo R, Neri A, Pellini F, Sensi C, Scomersi S, Taffurelli M, Bagnardi V, Oriecuia C, Pagan E, Sangalli C, Dessena M, Veronesi P, Galimberti V. Lissidini G, et al. Among authors: fabi a. Breast Cancer Res Treat. 2024 Nov;208(1):29-40. doi: 10.1007/s10549-024-07380-0. Epub 2024 Jun 19. Breast Cancer Res Treat. 2024. PMID: 38896332
Sacituzumab Govitecan for the treatment of advanced triple negative breast cancer patients: a multi-center real-world analysis.
Caputo R, Buono G, Piezzo M, Martinelli C, Cianniello D, Rizzo A, Pantano F, Staropoli N, Cangiano R, Turano S, Paris I, Nuzzo F, Fabi A, De Laurentiis M. Caputo R, et al. Among authors: fabi a. Front Oncol. 2024 Mar 26;14:1362641. doi: 10.3389/fonc.2024.1362641. eCollection 2024. Front Oncol. 2024. PMID: 38595817 Free PMC article.
Neuroendocrine neoplasms of the breast: a multicenter retrospective Italian study.
Baldelli R, Franco M, Renzelli V, DE Fata R, Visca P, Macciomei MC, Fabi A, Rossi V, Faggiano A, Rizza L, Rota F, Appetecchia M, Vecchione A, Lania A, Antonini S, Botticelli A, Verrico M, D'Amati G, Pignataro MG, Cerbelli B, Bianchi A, LA Salvia A, Zuppi P, Rindi G; SIE (Società Italiana di Endocrinologia). Baldelli R, et al. Among authors: fabi a. Minerva Endocrinol (Torino). 2024 Dec 11. doi: 10.23736/S2724-6507.24.04200-3. Online ahead of print. Minerva Endocrinol (Torino). 2024. PMID: 39660883
Treating advanced breast cancer with metronomic chemotherapy: what is known, what is new and what is the future?
Cazzaniga ME, Biganzoli L, Cortesi L, De Placido S, Donadio M, Fabi A, Ferro A, Generali D, Lorusso V, Milani A, Montagna E, Munzone E, Orlando L, Pizzuti L, Simoncini E, Zamagni C, Pappagallo GL; “Metronomic Chemotherapy in Advanced Breast Cancer” Study Group. Cazzaniga ME, et al. Among authors: fabi a. Onco Targets Ther. 2019 Apr 23;12:2989-2997. doi: 10.2147/OTT.S189163. eCollection 2019. Onco Targets Ther. 2019. PMID: 31114242 Free PMC article.
Breaking barriers in triple negative breast cancer (TNBC) - Unleashing the power of antibody-drug conjugates (ADCs).
Dri A, Arpino G, Bianchini G, Curigliano G, Danesi R, De Laurentiis M, Del Mastro L, Fabi A, Generali D, Gennari A, Guarneri V, Santini D, Simoncini E, Zamagni C, Puglisi F. Dri A, et al. Among authors: fabi a. Cancer Treat Rev. 2024 Feb;123:102672. doi: 10.1016/j.ctrv.2023.102672. Epub 2023 Dec 14. Cancer Treat Rev. 2024. PMID: 38118302 Free article. Review.
332 results